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needle biopsies is a diagnostic challenge. The gold standard for detection of HGPIN and BCH is
histopathological examination; however subjectivity in interpretation and tiny volume of obtained
tissue hamper reliable diagnosis.
Aims: The aim of this study was to assess usefulness of using the p63 and p504s to solve this prob-
lem. Although the use of p63 and p504s is now well established in differentiation between preneo-
plastic and neoplastic prostatic lesions, their usefulness in tiny tissue material is, however, not fully
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16 Fatma EZ Salah ED Yassin et al.Methods: The study included a spectrum of 30 prostatic needle biopsies (5 BCH, 10 HGPIN, 10
indeﬁnite luminal proliferations where BCH and HGPIN could not be distinguished from each
other and 5 adenocarcinomas). H&E stained sections were examined for histopathological features.
Other sections were stained immunohistochemically with p63 and p504s.
Results: The mean age of patients was 69 (SD = 7.6) years. PSA range was 1.3–2.7 ng/ml. Ultra-
songraphic ﬁndings were unremarkable. All BCH showed p504s/p63+ pattern, All HGPIN had
p504s+/p63+ pattern while carcinomas were p504s+/p63. After immunostaining combined with
histopathological features; the 10 indeﬁnite specimens could be diagnosed as 4 BCH and 6 HGPIN.
The article explains how applying this staining pattern on the challenging specimens, combined with
histopathological features, can be helpful in proper identiﬁcation of prostatic proliferations.
ª 2013 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.
Open access under CC BY-NC-ND license.Introduction
Prostatic epithelial cell proliferations span a spectrum of le-
sions starting from ordinary BCH, ﬂorid BCH to PIN ending
by adenocarcinoma [1]. BCH arises from terminal ducts and
acini usually of peripheral glands. The lesion is reported in
about 10% of prostatic needle biopsy [2]. Two types of BCH
were described; Typical and atypical. Proliferating basal cells
in typical type consist of two or more cell layers. Cells are char-
acteristically larger than usual cells, basophilic in appearance
with scanty cytoplasm, have round to slightly ovoid nuclei
with absent to inconspicuous nucleoli [2]. Cells in atypical
BCH are characterized by having prominent nucleoli, but are
otherwise identical to ordinary BCH [3]. Atypical BCH is diag-
nosed if more than 10% of the basal cells exhibited prominent
nucleoli [2]. Prostatic intraepithelial neoplasia (PIN) is charac-
terized by a neoplastic transformation of the secretory epithe-
lium within preexisting benign prostatic acini or ducts [4]. The
lesion was originally graded from 1 to 3 [5], but currently a
simpliﬁed, two-tier classiﬁcation has been recommended: low
grade (grade 1) and high grade (grades 2 and 3) [5]. Low-grade
PIN (LGPIN) is not a risk factor for subsequent adenocarci-
noma [4], whereas HGPIN is a precancerous lesion possessing
most of the phenotypic, biochemical, and genetic changes of
prostatic carcinoma but without invasion of the basement
membrane [5]. Early stromal microinvasion, the earliest evi-
dence of carcinoma, occurs at sites of acinar outpouching
and basal cell disruption in acini with HGPIN in about 2%
of high-power microscopic ﬁelds of PIN [6,7].
P63 is a member of the p53 gene family, located on human
chromosome 3q27–29. The encoded protein is widely ex-
pressed in human tissues, particularly in basal cells of many
epithelial tissues such as the epidermis, cervix, urothelium,
and prostate [8]. P63 staining is a sensitive marker in identify-
ing basal cells in benign lesions and therefore was reported to
help to avoid misdiagnoses of malignancy in prostatic needle
biopsies where diagnosis of malignancy is often based on the
absence of basal cells [9].
In 2000, Xu and colleagues identiﬁed three genes: p503s,
p504s and p510s that showed differential expression in benign
and malignant prostate glands using cDNA subtraction in
conjunction with cDNA microarray screening. p504s; one of
the gene products named with cDNA clone number, was
clearly identiﬁed as human alpha-methylacyl coenzyme A rac-
emase (AMACR) [10]. Ordinary BCH lacks AMACR/p504s
immunoreactivity however, rarely, scant individual positive
AMACR/p504s cells could be found in ﬂorid BCH [11]. Incontrast, both HGPIN and prostate cancer show expression
of AMACR/p504s in several reports [12,13].
Basal cell proliferations have the same immunophenotype of
basal cells present in normal ducts and acini [1]. Montironi et al.
suggested that basal cell proliferations should be strongly posi-
tive for p63 and negative for p504s. HGPIN might have a high
degree of basal cell disruption. This feature is best demonstrated
with disruption of nuclear p63 immunohistochemical expres-
sion [4]. HGPIN adjacent to prostatic adenocarcinoma shows
a greater degree of basal-cell disruption than HGPIN distal to
cancer [14]. Similar to adenocarcinoma, the cytoplasm of cells
in most cases of HGPIN showed positive AMACR [15].
Because both BCH and HGPIN do not result in a signiﬁ-
cant elevation of serum PSA [16,17] and both cannot be de-
tected clinically or through imaging, the histopathological
evaluation is considered the gold standard for the diagnosis
of the two entities [18]. Although the use of p63 and p504s
markers is now well established in differentiation between pre-
neoplastic and neoplastic prostatic lesions, their usefulness in
tiny tissue material is, however, not fully studied. The aims
of the current study were (1) to assess the usefulness of p63
and p504s markers in the histopathological differential diagno-
sis between BCH and HGPIN in tiny prostatic needle biopsies
and (2) to examine histopathological morphological character-
istics of both lesions with assessment of the interobserver var-
iability in lesion diagnosis.
Material and methods
Patients and tissue samples
One hundred specimens of prostatic needle biopsy were re-
trieved from the Pathology Department, Sohag University
Hospital during the period from 2009 to 2010. Revision of
100 H&E stained slides revealed the following diagnoses; thirty
deﬁnite prostatic adenocarcinoma (PAC), 20 pure BPH, 15
HGPIN with foci of adenocarcinoma, 4 solid pattern of
BCH and 6 LGPIN. Because the aim of the study was to exam-
ine usefulness of using immunohistochemical tools for differ-
entiation between BCH and HGPIN, only specimens which
carry foci with luminal proliferations were identiﬁed for the
study (25 specimens). These specimens fulﬁll the following
inclusion criteria:
1. Stratiﬁcation of epithelium within the pre-existing ducts or
acini (two layers or more) with preservation of the lumen
even if it was small or eccentric.
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atypia (mainly; prominent nucleoli).
3. Absence of true cribriform glands (single glandular units
with punched out lumina) while the pseudocribriform
glands (fused individual hyperplastic acini) could be
included [19].
4. The glandular architecture is still retaining a benign
pattern.
5. Exclude cases of PIN associated with prostatic
adenocarcinoma.
6. Benign prostatic hyperplasia can be considered as an asso-
ciated ﬁnding.
Five cases of deﬁnite prostate adenocarcinoma were also in-
cluded as the control group, their Gleason’s Score ranged from
6 to 8. Foci of BPH were considered as internal control. Clin-
icopathological data of the 30 (25 luminal proliferations and 5
control) prostatic needle biopsy specimens were retrieved from
the clinical reports to assess the clinicopathological criteria,
PSA level and sonographic ﬁndings.
After reviewing the literature a constellation of features dis-
tinguishing BCH from HGPIN including architecture, cytolog-
ical features were used in the following study to identify each
of the 25 specimens on H&E sections as mentioned in
Table 1.(Modiﬁed from [1]). According to the criteria in Ta-
ble 1, the 25 studied specimens were grouped as follows after
examination of H&E sections: First group: BCH (5 cases) asso-
ciated with BPH. Second group: HGPIN (10 cases). Third
group: 10 cases in which the nature of basal or luminal epithe-
lial cell proliferation was difﬁcult to be assessed (these cases
were previously diagnosed as BPH).Immunohistochemistry
Representative formalin-ﬁxed, parafﬁn embedded routinely-
processed, tissue sections from each specimens were stained
with 1:50 Rabbit Polyclonal p504s (AMACR) antibody (CP
200 AK, BK, CK, Biocare Medical, USA in Renaissance
Background Reducing Diluent; PD905, BioCare Medical,
USA) and 1:100 Mouse Monoclonal p63 antibody (Clone
4A4, Lab Vision Corporation, USA in phosphate buffered sal-
ine; PBS, pH 7.2).Table 1 Comparing histopathological features between BCH and H
BCH
Architectural
patterns
Cells form small solid bas
– acinar or pseudocribrifo
Cells Atypical looking basal ce
seen underlying the benig
secretory cells
Nuclei Rounded and central
Nucleoli May be present in atypica
Atypia Minimal to mild, mainly
of prominent nucleolus
Associated
conditions
Inﬂammation, BPH and/oStaining procedure
Brieﬂy, tissue sections were deparafﬁnized and rehydrated, anti-
gens were retrieved by incubating sections in 0.01 mol/L sodium
citrate buffer (pH 6.0) in a 800w microwave for 20 min. After
blocking nonspeciﬁc reactions by endogenous hydrogen perox-
idase, sections were incubated at room temperature with p63
and p504s for one hour and two hours, respectively. Visualiza-
tion of staining was conducted using strept-avidin-bioten; ABC
staining kit (Catalog # TA-015-HP, LabVision Corporation
Fremont, USA), according to the manufacturer’s instructions.
Immunohistochemical reactions were developed with 3,3-diam-
inobenzidine; chromogenic peroxidase substrate (DAB).
Counterstaining of tissue sections was done using Myer’s
Hematoxylin and mounted using DPX and cover slipped.
Sections of deﬁnite prostatic adenocarcinoma and benign
prostatic hyperplasia (BPH) associated with BCH were used
as positive controls for p504s and p63, respectively. Both posi-
tive and negative controls were consistently immunoreactive
and lacking reactivity respectively. This conﬁrms the validity
of the staining results.
Assessment of p504s immunostaining
Positive p504s staining was identiﬁed as cytoplasmic and/or
luminal staining within the epithelial cells. P504s expression
was evaluated in BPH, BCH, PIN, and prostatic adenocarci-
noma. The extent of staining was evaluated as follows: 0:
(none) absent. 1: (<5%) minimal. 2: (5–50%) focal, or 3:
(>50%) diffuse. The intensity was graded as follows: 0: nega-
tive, 1: weak, 2: moderate or 3: strong [20].
Assessment of p63 immunostaining
P63 appeared as brown nuclear staining in the basal cells.
Staining results were continuous, patchy or negative. Internal
positive control in the form of nuclear staining of either en-
trapped or dispersed basal layer of benign glands was found
in some sections.
Statistical analysis
Statistical analysis was performed using the software package
SPSS for Windows, version 15: (a) a 2 · 2 table and Fisher0sGPIN.
HGPIN
al cell nests
rm
Stratiﬁcation of epithelium form; ﬂat-tufting –
micropapillary and cribriform but do not occlude
the glandular lumina
ll can be
n appearing
Full thickness cytological atypia seen in luminal
cells while the basal cells appear unremarkable
Round to ovoid and perpendicular to the basement
membrane
l BCH Usually present, their absence may be due to poor
ﬁxation or staining
in the form Minimal, moderate and severe
r atrophy Adenocarcinoma of the prostate
18 Fatma EZ Salah ED Yassin et al.Exact test were conducted to examine for statistical signiﬁcant
differential expression of p63 and p504s in the BCH, HGPIN,
and adenocarcinoma. All statistical analyses were two-sided
and signiﬁcance was deﬁned as P< 0.05.
Results
The thirty specimens of prostatic needle biopsy included 5
cases of deﬁnite prostatic adenocarcinoma. The main attribute
in the other 25 cases is the presence of glandular proﬁles lined
by several layers of epithelial cells with retained central lumen.
In the 25 patient cohort, patient ages ranged from 54 toFigure 1 A spectrum of prostatic lesions including normal prostatic
(ﬁrst raw right), BCH (2nd raw), HGPIN (3rd raw) and PAC (raw at t
panels in right column are stained with p504s. Single continuous layer o
multiple layers of p63 basal cells are seen in BCH (C · 100). Basal cells
Staining with p504s showed negative staining in benign acini among st
moderate to strong positive cytoplasmic reactivity detected in HGPIN86 years with mean age of 69 (SD = 7.6) years. Their PSA le-
vel ranged from 1.3 to 2.7 ng/ml. Their sonographic ﬁndings
were unremarkable.
Histomorphological features of BCH; N = 5 and HGPIN;
N = 10 in H&E stained sections
BCH
The included ﬁve cases of BCH revealed variable sized pros-
tatic acini with focal or diffuse circumferential proliferation
of basal cells; at least two cell layers’ thickness. The lumen
of prostatic acini is usually preserved. The recognized patternsacini (ﬁst raw) left, benign acini (arrows) within adenocarcinoma
he bottom). Four panels in left column are stained with p63. Four
f p63-positive basal cells is seen in normal acini (A · 100). Positive
are interrupted in HGPIN (B · 200) and absent in PAC (G · 200).
rongly positive PAC glands (A · 200), negative in BCH (D · 100),
(F · 200) and PAC (H · 200), respectively.
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iform in one case. The basal cells had small, rounded to slightly
ovoid nuclei, with absent to inconspicuous nucleoli. The cyto-
plasm of basal cells appeared as a dark narrow rim with incon-
spicuous cell margins. Preservation of an inner layer of luminal
cells was often noted. The luminal cells showed abundant cyto-
plasm with a slightly basophilic appearance, an easily identiﬁ-
able cell membrane and nuclei with open chromatin and
occasional small nucleoli. The borders between the basal and
the luminal cells were not easily recognized. The surrounding
prostatic tissue showed BPH.
HGPIN
The glandular proﬁles of the ten cases of HGPIN were varied
from tufted, ﬂat to micropapillary patterns. Within the prolifer-
ating acini there is crowding and stratiﬁcation of the nuclei with
occasional nucleoli. Nuclei toward the center of the gland tend
to have bland cytology compared to peripherally located nuclei.
The individual cells are uniformly enlarged with increased N/C
ratio.Most of cells showed coarse clumped chromatin along the
nuclear membrane and frequent nucleoli were noticed.
Immunohistochemical proﬁles of the control and the third
(unknown) groups
Control group (prostatic adenocarcinoma; PAC)
P504s immunostaining. Diffuse positive strong cytoplasmic
expression of P504s was detected in all ﬁve prostatic needleTable 2 Detailed staining pattern of p63 and p504s in HGPIN and
HGPIN Number BC
Histopathological patterns
Tufted 6 Stra
Flat 9
Micropapillary 1 Pse
P504s staining
Staining pattern Neg
Positive focal moderate luminal 4
Positive focal weak luminal 2
Positive diﬀuse weak luminal 2
Positive diﬀuse moderate luminal 6
Positive diﬀuse strong luminal 2
P63 staining (nuclear/basal)
Positive(continuous) 3 Stro
Positive (fragmented) 13
Table 3 Summary for P63 and p504s in a spectrum of prostatic les
Control group of p504s
(PAC) (N= 5)
HGPIN (N=
P63 (nuclear stain) Negative
5/5 (100%)
Positive
Continuous 3
Fragmented 1
P504s (cytoplasmic stain) Positive
Strong 5/5 (100%)
Positive
Weak 4/16 (2
Moderate 10/
Strong 2/16(1
PAC, prostatic adenocarcinoma; HGPIN, high grade intraepithelial neopbiopsy specimens of prostatic adenocarcinoma. The staining
was circumferential and luminal (Fig. 1H).
P63 immunostaining. There was negative nuclear staining (ab-
sence of basal cells) in all ﬁve prostatic needle biopsy speci-
mens of prostatic adenocarcinoma (Fig. 1G). Positive
internal control appeared clearly in the adjacent benign glands
(Fig. 1A).
The third (unknown) group (N = 10)
Four cases showed continuous nuclear p63 immunostaining of
the stratiﬁed epithelium and complete negative cytoplasmic
p504s staining within the prostatic acini indicating the basal
cell nature of the stratiﬁed epithelium. The other six cases
showed fragmented nuclear p63 immunostaining of the basal
layer and moderate circumferential luminal cytoplasmic
p504s of the stratiﬁed luminal cells.
After application of immunohistochemical p63 and p504s
to the 3rd group, and constellation of the previous histopathol-
ogical features of BCH and HGPIN; the 10 unknown speci-
mens were diagnosed as: 4 BCH and 6 HGPIN.
Summary of the immunohistochemical features of BCH (N = 9
cases) and HGPIN (N= 16 cases) as follows (Table 2)
Expression of p63 in BCH versus HGPIN
The nine (100%) specimens of BCH showed dark brown nucle-
ar p63 staining in the basal cells in the form of multilayerBCH.
H Number
tiﬁcation with preservation of lumen (Acinar) 6
udocribriform 3
ative All
ngly positive in 2–3 layers All
ions.
16) BCH (N= 8) Control of p63 (BPH)
/16 (19%)
3/16 (81%)
Positive
Multilayer 8/8 (100%)
Positive
Continuous single layer
5%)
16 (62.5%)
2.5%)
Negative 8/8 (100%) Negative
lasia; BCH, basal cell hyperplasia.
Table 4 Summary for the statistical analysis tables in Fisher’s Exact test.
Lesion type Number P504s P63
Negative Positive Negative Positive
BCH 8 8 0 0 8
HGPIN 16 0 16 0 16
PCA 5 0 5 5 0
Fisher’s Exact test P values <0.001 <0.001
20 Fatma EZ Salah ED Yassin et al.(ranged from 2 to 4 cell thick) (Fig. 1C). Negative p63 staining
of luminal cells was noticed. The basal cell layer was identiﬁed
as a single layer with p63 brown nuclear staining in 16/16
(100%) of HGPIN; 3/16 (19%) were in a continuous fashion
and 13/16 (81%) were fragmented (Fig. 1E).
Expression of p504s in BCH versus HGPIN
Basal cell layers within the proliferating prostatic acini showed
complete cytoplasmic AMACR/p504s negativity in all 9 speci-
mens of BCH (Fig. 1D). Two specimens of HGPIN showed
strong AMACR/p504s immunostaining, ten specimens showed
moderate staining and four specimens showed weak staining
(Fig. 1F). AMACR/p504s expression was diffuse in 10 and fo-
cal in 6 specimens of HGPIN. The distribution was circumfer-
ential in 10 specimens of HGPIN and luminal in the other 6
specimens. Using Fisher’s Exact test, there was a high signiﬁ-
cant difference in staining patterns of both p63 and p504s be-
tween BCH and HGPIN, P < 0.001 for p63 and P < 0.001
for p504s. Detailed staining pattern of p63 and p504s in
HGPIN and BCH is mentioned in Table 2. Summary for
p63 and p504s in the spectrum of prostatic lesions including
PAC and BPH is mentioned in Tables 3 and 4.Discussion
BCH is a well recognized entity on TUR specimens however;
its presence on prostatic needle biopsies is a diagnostic chal-
lenge [21]. Growth of BCH is often focal in the prostatic
peripheral zone causing difﬁculty in differentiation from
HGPIN on needle core biopsies [2,22]. The gold standard for
detection of HGPIN and BCH is histopathological examina-
tion of biopsy samples because both lesions cannot be sus-
pected clinically [1]. BCH is not a precursor of HGPIN or
adenocarcinoma, whereas HGPIN is a pre-malignant lesion
[18]. Therefore, the management of both lesions differs. Accu-
rate diagnosis should be done to avoid over-diagnosis of BCH
or under-diagnosis of HGPIN. This study was designed to dif-
ferentiate between both lesions using an immunohistochemical
tool.
Peripheral BCH and HGPIN share the following features:
both lesions are histological mimickers [4]. Both conditions
are not uncommon ﬁndings on prostatic needle biopsies. Thor-
son and colleagues reported BCH in 10% of needle core biop-
sies from the peripheral zone [2], a ﬁgure close to what was
found in the current study (9%). The frequency of HGPIN
on needle biopsies ranges from 0.7% to 20% [23], this comes
in agreement with our results which lie within the same range
(16%). Tiny volume of prostatic tissue on needle biopsy makes
the distinction between BCH and HGPIN problematic. Fur-
thermore, the technical problems like poor ﬁxation or staining
of the slides making the reliability of histological atypical signslike prominent nucleolus is uncertain or unreliable [18]. Both
BCH and HGPIN cannot be suspected clinically or by ultraso-
nographic examination. Imaging of all BCH and PIN speci-
mens in the current study did not detect any suspicious mass
similar to what was reported previously [2]. The same ﬁndings
were mentioned in a previous report [5] emphasizing that PIN
is an accidental microscopic ﬁnding below the detection
threshold by transrectal ultrasound. Both conditions do not
elevate PSA level; it ranges from 1.0 to 2.5 ng/ml in BCH
[17] which is considered a normal range. Similar ﬁndings were
detected in the current study (1.3–2.7 ng/ml). It was reported
that isolated HGPIN is not associated with an elevated serum
PSA because of the intact basement membrane. PSA produced
by neoplastic cells in PIN is not released into serum at clini-
cally signiﬁcant levels. Any elevated PSA level in PIN should
raise an alarm to search for adjacent focus of cancer prostate
[16].
The management of patients with HGPIN differs from oth-
ers with BCH. BCH is not a precursor of HGPIN or adenocar-
cinoma. Additionally, the presence of BCH in the peripheral
zone needle biopsy samples was signiﬁcantly associated with
the absence rather than the presence of adenocarcinoma [2].
BCH is therefore a benign condition and no need for further
biopsy [24]. In contrast, HGPIN is a premalignant condition,
its identiﬁcation warrants repeated biopsy for concurrent or
subsequent invasive carcinoma that was reported in 30–75%
of HGPIN [5,24,25]. The accurate diagnosis of both conditions
(HGPIN and BCH) should be done to avoid over diagnosis of
BCH or under diagnosis of HGPIN.
The distinction between BCH (with/without prominent
nucleoli) and HGPIN may not be difﬁcult at H&E stained sec-
tions if they have clear architectural and cytological features as
mentioned in Table 1. The ﬁnding of small, solid, basaloid
nests is a diagnostic clue pointing toward BCH because such
nesting is not typical of HGPIN [26].
However, the distinction of BCH from HGPIN becomes
difﬁcult on H&E examination if they have the following
criteria – as demonstrated by our work and others [24,27,28]:
Similar growth patterns, stratiﬁcation of epithelium within
pre-exciting ducts and acini, little or no cellular atypia and
benign looking of both conditions especially if HGPIN is
not associated with micro invasion or deﬁnite prostatic
adenocarcinoma.
As a point of interest, we and Thorson found the presence
of inﬂammation in majority of BCH specimens [2]. Such ﬁnd-
ing suggests that peripheral zone BCH in untreated patients
may represent a stereotyped response to injury such as that
sustained because of inﬂammation. Thus, the multilayering
of epithelium within prostatic ducts or acini could not be
solved in all instances at level of H&E examination slides;
therefore the use of immunohistochemical markers to identify
the nature of the epithelial cell proliferation is mandatory.
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cells and to recognize the multilayered BCH. The marker there-
fore helps to avoid misdiagnoses of malignancy in prostatic
needle biopsies. Moreover, staining of cells other than basal
cells was not observed, indicating that its use would not lead
to false-negative diagnoses [29]. Although HGPIN retains an
intact or fragmented basal cell layer, prostatic adenocarcinoma
does not [30]. Increasing grades of PIN were found to be asso-
ciated with progressive disruption of the basal cell layer [31].
AMACR/p504s is a member of the gene family; over ex-
pressed in prostate cancer. Ordinary BCH was found to lack
AMACR/p504s immunoreactivity however, rarely, scant indi-
vidual positive AMACR/p504s cells could be found in ﬂorid
BCH. Several reports showed that AMACR/p504s is expressed
in both HGPIN and prostate cancer [12,13].
In the current study, the combined use of AMACR/p504s
and p63 helped to distinguish BCH from HGPIN in prostatic
needle biopsies. In nine cases (100%) of BCH immunostaining
showed negative expression of AMACR/p504s and character-
istic expression of basal cell marker (p63) in the form of con-
tinuous multilayer nuclear staining of the proliferating
epithelium. The previous ﬁndings were similar to what was
mentioned by Hosler and Epstein [21], they reported the use
of the immunohistochemical method as a useful tool for the
identiﬁcation of the nature of basal cell proliferation. They
found 100% (7/7) positivity for p63 in cases of basal cell hyper-
plasia with complete negative expression for p504s.
Yang and colleagues [8] conducted a comparative study be-
tween BCH (11 cases) and limited adenocarcinoma of the pros-
tate (15 cases) by immunohistochemical methods. They found
that p63 was positive in all BCH (100%) but negative in all
prostatic carcinoma. On the other hand p504s was negative
in hyperplastic basal cells but positive in carcinoma. Similar
ﬁndings were also reported by other studies [4,27].
Immunostaining of AMACR/p504s showed moderate to
strong expression in 16/16 (100%) of HGPIN biopsies. P63
expression in these lesions was limited to a single basal layer
of challenging stratiﬁed epithelium; this expression proﬁle of
both AMACR/p504s and p63 came in agreement with previ-
ous studies and supported our diagnosis as HGPIN [4,23,32].
Whereas, Kunju and colleagues [12] found the same pattern
of p504s/p63 expression in 89% of HGPIN. Another study
[33] with larger numbers of cases reported positive expression
of p504s in 90% (126 of 140 cases) of HGPIN. Moreover,
Ananthranarayanan et al. [34] demonstrated the same staining
proﬁle of p504s/p63 in 45 patients with isolated HGPIN in
needle core biopsy.
Although combined use of both markers (p504s & p63) is
extremely helpful, they should be used cautiously and always
in conjunction with conventional H&E histological assess-
ment, as there is a spectrum of benign and malignant lesions
sharing the previous immunoproﬁle which are outside our
scope (e.g., atypical adenomatous hyperplasia).Conclusion
The distinction between BCH and HGPIN is a challenging his-
topathological problem using conventional methods in tiny
prostatic biopsies. Combined use of AMACR/p504s and p63
may be helpful in reaching a deﬁnite diagnosis where HGPIN
are positive for both p63 and AMACR/p504s while BCH arepositive for p63 and lack of AMACR/p504s expression. Be-
cause of the small number of specimens used in this study,
we recommend conducting a similar study on bigger number
of specimens before recommending use of both markers in dai-
ly practical histopathological diagnosis.Conﬂict of interest
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